<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611545</url>
  </required_header>
  <id_info>
    <org_study_id>AIHG-1410-Clopidogrel</org_study_id>
    <nct_id>NCT01611545</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics and Effective Treatment With Clopidogrel</brief_title>
  <official_title>Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avera McKennan Hospital &amp; University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avera Heart Hospital of South Dakota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avera McKennan Hospital &amp; University Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this biospecimen repository is to evaluate an individual's genotype, identify the
      variances, and understand how they relate to treatment with clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this project is to distinguish genetic profiles that will assist a
      practitioner in determining the right dose or alternate medication for the patient. In
      partnership with the genetics team of the Avera Institute for Human Genetics and physicians
      with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research
      team will perform genetic analysis to identify genetic variances.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Pharmacogenomics and Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <description>Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Pharmacogenomics</intervention_name>
    <description>Utilizing pharmacogenomics to determine the most effective treatment</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood or buccal samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of either the Avera Heart Hospital of South Dakota or North Central Heart
        Institute who have been precribed Clopidogrel or are being considered for treatment with
        Clopidogrel.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently taking or prescribed Clopidogrel or under consideration

          -  Acute/interventionPatients of the Avera Heart Hospital

          -  Cardiology clinic patients with the Avera Heart Hospital and North Central Heart
             Institute

        Exclusion Criteria:

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gareth Davies, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Avera McKennan Hospital &amp; University Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avera Institute for Human Genetics</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.Avera-Research.org</url>
    <description>Avera Research Institute website</description>
  </link>
  <reference>
    <citation>Topol EJ, Schork NJ. Catapulting clopidogrel pharmacogenomics forward. Nat Med. 2011 Jan;17(1):40-1. doi: 10.1038/nm0111-40.</citation>
    <PMID>21217678</PMID>
  </reference>
  <reference>
    <citation>Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23;306(20):2221-8. doi: 10.1001/jama.2011.1703. Epub 2011 Nov 16.</citation>
    <PMID>22088980</PMID>
  </reference>
  <reference>
    <citation>Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.</citation>
    <PMID>19706858</PMID>
  </reference>
  <reference>
    <citation>Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75. doi: 10.1056/NEJMoa0808227. Epub 2008 Dec 22.</citation>
    <PMID>19106083</PMID>
  </reference>
  <reference>
    <citation>Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. Review.</citation>
    <PMID>22203539</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Plavix</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

